Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK in Relapsed or Refractory AML
NCT05247957Phase 1Terminated
- Sponsor
- Hangzhou Cheetah Cell Therapeutics Co. Ltd.
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR NK cells in acute myeloid leukemia (AML), sponsored by Hangzhou Cheetah Cell Therapeutics Co. Ltd. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximal Tolerable Dose at 28 days. Started Oct 2021; status: terminated.
02
Drugs
NKG2D CAR NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05247957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247957.